tiprankstipranks
Trending News
More News >
Moderna (MRNA)
NASDAQ:MRNA
US Market
Advertisement

Moderna (MRNA) Stock Forecast & Price Target

Compare
17,707 Followers
See the Price Targets and Ratings of:

MRNA Analyst Ratings

Hold
20Ratings
Hold
3 Buy
13 Hold
4 Sell
Based on 20 analysts giving stock ratings to
Moderna
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

MRNA Stock 12 Month Forecast

Average Price Target

$41.60
▲(55.57% Upside)
Based on 20 Wall Street analysts offering 12 month price targets for Moderna in the last 3 months. The average price target is $41.60 with a high forecast of $198.00 and a low forecast of $12.00. The average price target represents a 55.57% change from the last price of $26.74.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"$11","58":"$58","105":"$105","152":"$152","199":"$199"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":198,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$198.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":41.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$41.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,58,105,152,199],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.6,40.70769230769231,53.815384615384616,66.92307692307693,80.03076923076924,93.13846153846154,106.24615384615385,119.35384615384615,132.46153846153845,145.56923076923076,158.67692307692306,171.78461538461536,184.8923076923077,{"y":198,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.6,28.676923076923078,29.753846153846155,30.83076923076923,31.907692307692308,32.98461538461539,34.06153846153846,35.13846153846154,36.215384615384615,37.292307692307695,38.36923076923077,39.44615384615385,40.52307692307693,{"y":41.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.6,26.400000000000002,25.200000000000003,24,22.8,21.6,20.4,19.2,18,16.8,15.6,14.399999999999999,13.2,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":63.93,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.63,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.26,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":41.58,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":39.42,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":30.96,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":27.16,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":27.03,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":27.05,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":28.69,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 45, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":27.6,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 44, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":24.19,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":27.6,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$198.00Average Price Target$41.60Lowest Price Target$12.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
William Blair Analyst forecast on MRNA
William Blair
William Blair
Hold
Reiterated
10/23/25
Moderna's CMV Vaccine Trial Setback Leads to Hold Rating Amid Financial Reevaluation
Bank of America Securities Analyst forecast on MRNA
Bank of America Securities
Bank of America Securities
$24
Sell
-10.25%
Downside
Reiterated
10/23/25
Moderna's Financial Challenges: Declining Vaccine Sales and High Cash Burn Rate Lead to Sell Rating
Evercore ISI Analyst forecast on MRNA
Evercore ISI
Evercore ISI
$32$28
Hold
4.71%
Upside
Reiterated
10/23/25
Evercore ISI Sticks to Its Hold Rating for Moderna (MRNA)
Needham
Hold
Reiterated
10/23/25
Needham Remains a Hold on Moderna (MRNA)
J.P. Morgan Analyst forecast on MRNA
J.P. Morgan
J.P. Morgan
$25
Sell
-6.51%
Downside
Reiterated
10/23/25
J.P. Morgan Keeps Their Sell Rating on Moderna (MRNA)
TD Cowen
$25
Hold
-6.51%
Downside
Reiterated
10/23/25
TD Cowen Remains a Hold on Moderna (MRNA)with no changes to our $25 price target and Hold (2) rating.
Citi
$30$28
Hold
4.71%
Upside
Reiterated
10/23/25
Moderna's Hold Rating: Impact of CMVictory Study and Vaccine Program Risks
Leerink Partners Analyst forecast on MRNA
Leerink Partners
Leerink Partners
$16$12
Sell
-55.12%
Downside
Reiterated
10/23/25
Moderna (MRNA) Receives a Sell from Leerink PartnersWe reduce our PT to $12 (from $16) and reiterate an Underperform rating.
UBS
$40
Buy
49.59%
Upside
Reiterated
10/23/25
Optimistic Outlook on Moderna's Oncology Pipeline Amid CMV Setbacks: Buy Rating Reiterated
Piper Sandler Analyst forecast on MRNA
Piper Sandler
Piper Sandler
$69
Buy
158.04%
Upside
Reiterated
10/23/25
Piper Sandler Reaffirms Their Buy Rating on Moderna (MRNA)
Goldman Sachs Analyst forecast on MRNA
Goldman Sachs
Goldman Sachs
$35$34
Hold
27.15%
Upside
Reiterated
10/22/25
Hold Rating on Moderna Amid CMV Vaccine Setback and Oncology Pipeline Optimism
Bernstein
$28
Hold
4.71%
Upside
Assigned
10/21/25
Moderna (MRNA) Gets a Hold from Bernstein
Oppenheimer Analyst forecast on MRNA
Oppenheimer
Oppenheimer
Hold
Reiterated
10/20/25
Oppenheimer Reaffirms Their Hold Rating on Moderna (MRNA)
Barclays Analyst forecast on MRNA
Barclays
Barclays
$31
Hold
15.93%
Upside
Reiterated
10/20/25
Analysts' Opinions Are Mixed on These Healthcare Stocks: Moderna (NASDAQ: MRNA), Telix Pharmaceuticals (Other OTC: TLPPF) and Geron (NASDAQ: GERN)
Wolfe Research Analyst forecast on MRNA
Wolfe Research
Wolfe Research
$20
Sell
-25.21%
Downside
Reiterated
10/17/25
Moderna 'checking another mark' in oncology franchise, says Wolfe ResearchModerna 'checking another mark' in oncology franchise, says Wolfe Research
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
William Blair Analyst forecast on MRNA
William Blair
William Blair
Hold
Reiterated
10/23/25
Moderna's CMV Vaccine Trial Setback Leads to Hold Rating Amid Financial Reevaluation
Bank of America Securities Analyst forecast on MRNA
Bank of America Securities
Bank of America Securities
$24
Sell
-10.25%
Downside
Reiterated
10/23/25
Moderna's Financial Challenges: Declining Vaccine Sales and High Cash Burn Rate Lead to Sell Rating
Evercore ISI Analyst forecast on MRNA
Evercore ISI
Evercore ISI
$32$28
Hold
4.71%
Upside
Reiterated
10/23/25
Evercore ISI Sticks to Its Hold Rating for Moderna (MRNA)
Needham
Hold
Reiterated
10/23/25
Needham Remains a Hold on Moderna (MRNA)
J.P. Morgan Analyst forecast on MRNA
J.P. Morgan
J.P. Morgan
$25
Sell
-6.51%
Downside
Reiterated
10/23/25
J.P. Morgan Keeps Their Sell Rating on Moderna (MRNA)
TD Cowen
$25
Hold
-6.51%
Downside
Reiterated
10/23/25
TD Cowen Remains a Hold on Moderna (MRNA)with no changes to our $25 price target and Hold (2) rating.
Citi
$30$28
Hold
4.71%
Upside
Reiterated
10/23/25
Moderna's Hold Rating: Impact of CMVictory Study and Vaccine Program Risks
Leerink Partners Analyst forecast on MRNA
Leerink Partners
Leerink Partners
$16$12
Sell
-55.12%
Downside
Reiterated
10/23/25
Moderna (MRNA) Receives a Sell from Leerink PartnersWe reduce our PT to $12 (from $16) and reiterate an Underperform rating.
UBS
$40
Buy
49.59%
Upside
Reiterated
10/23/25
Optimistic Outlook on Moderna's Oncology Pipeline Amid CMV Setbacks: Buy Rating Reiterated
Piper Sandler Analyst forecast on MRNA
Piper Sandler
Piper Sandler
$69
Buy
158.04%
Upside
Reiterated
10/23/25
Piper Sandler Reaffirms Their Buy Rating on Moderna (MRNA)
Goldman Sachs Analyst forecast on MRNA
Goldman Sachs
Goldman Sachs
$35$34
Hold
27.15%
Upside
Reiterated
10/22/25
Hold Rating on Moderna Amid CMV Vaccine Setback and Oncology Pipeline Optimism
Bernstein
$28
Hold
4.71%
Upside
Assigned
10/21/25
Moderna (MRNA) Gets a Hold from Bernstein
Oppenheimer Analyst forecast on MRNA
Oppenheimer
Oppenheimer
Hold
Reiterated
10/20/25
Oppenheimer Reaffirms Their Hold Rating on Moderna (MRNA)
Barclays Analyst forecast on MRNA
Barclays
Barclays
$31
Hold
15.93%
Upside
Reiterated
10/20/25
Analysts' Opinions Are Mixed on These Healthcare Stocks: Moderna (NASDAQ: MRNA), Telix Pharmaceuticals (Other OTC: TLPPF) and Geron (NASDAQ: GERN)
Wolfe Research Analyst forecast on MRNA
Wolfe Research
Wolfe Research
$20
Sell
-25.21%
Downside
Reiterated
10/17/25
Moderna 'checking another mark' in oncology franchise, says Wolfe ResearchModerna 'checking another mark' in oncology franchise, says Wolfe Research
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Moderna

1 Month
xxx
Success Rate
28/45 ratings generated profit
62%
Average Return
+0.81%
reiterated a xxx
rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 62.22% of your transactions generating a profit, with an average return of +0.81% per trade.
3 Months
xxx
Success Rate
29/45 ratings generated profit
64%
Average Return
-5.41%
reiterated a xxx
rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 64.44% of your transactions generating a profit, with an average return of -5.41% per trade.
1 Year
Mani ForooharLeerink Partners
Success Rate
38/45 ratings generated profit
84%
Average Return
-0.97%
reiterated a sell rating 5 days ago
Copying Mani Foroohar's trades and holding each position for 1 Year would result in 84.44% of your transactions generating a profit, with an average return of -0.97% per trade.
2 Years
xxx
Success Rate
42/45 ratings generated profit
93%
Average Return
+33.27%
reiterated a xxx
rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 93.33% of your transactions generating a profit, with an average return of +33.27% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MRNA Analyst Recommendation Trends

Rating
Jun 25
Jul 25
Aug 25
Sep 25
Oct 25
Strong Buy
6
6
4
6
5
Buy
0
0
0
0
0
Hold
42
45
44
32
27
Sell
8
9
9
6
4
Strong Sell
0
0
0
0
0
total
56
60
57
44
36
In the current month, MRNA has received 5 Buy Ratings, 27 Hold Ratings, and 4 Sell Ratings. MRNA average Analyst price target in the past 3 months is 41.60.
Each month's total comprises the sum of three months' worth of ratings.

MRNA Financial Forecast

MRNA Earnings Forecast

Next quarter’s earnings estimate for MRNA is -$2.12 with a range of -$3.10 to -$1.31. The previous quarter’s EPS was -$2.13. MRNA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year MRNA has Preformed in-line its overall industry.
Next quarter’s earnings estimate for MRNA is -$2.12 with a range of -$3.10 to -$1.31. The previous quarter’s EPS was -$2.13. MRNA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year MRNA has Preformed in-line its overall industry.

MRNA Sales Forecast

Next quarter’s sales forecast for MRNA is $879.55M with a range of $610.94M to $1.43B. The previous quarter’s sales results were $142.00M. MRNA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year MRNA has Preformed in-line its overall industry.
Next quarter’s sales forecast for MRNA is $879.55M with a range of $610.94M to $1.43B. The previous quarter’s sales results were $142.00M. MRNA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year MRNA has Preformed in-line its overall industry.

MRNA Stock Forecast FAQ

What is MRNA’s average 12-month price target, according to analysts?
Based on analyst ratings, Moderna’s 12-month average price target is 41.60.
    What is MRNA’s upside potential, based on the analysts’ average price target?
    Moderna has 55.57% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is MRNA a Buy, Sell or Hold?
          Moderna has a consensus rating of Hold which is based on 3 buy ratings, 13 hold ratings and 4 sell ratings.
            What is Moderna’s price target?
            The average price target for Moderna is 41.60. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $198.00 ,the lowest forecast is $12.00. The average price target represents 55.57% Increase from the current price of $26.74.
              What do analysts say about Moderna?
              Moderna’s analyst rating consensus is a Hold. This is based on the ratings of 20 Wall Streets Analysts.
                How can I buy shares of MRNA?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis